Boehringer Ingelheim has obtained ad-interim injunctions against four domestic pharmaceutical companies that launched generic versions of Boehringer Ingelheim’s patent-protected drug Linagliptin, which is marketed under the brand name, Trajenta. 

The recent injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making, using, offering for sale, selling, importing and/or exporting in any form in India either by themselves or through their directors, partners licenses, stockist and distributors, agents etc., jointly and severally until the next date of hearing. Boehringer Ingelheim holds a valid patent for Linagliptin in India until August 2023. 

Vani Manja, MD, Boehringer Ingelheim India, said, “The swift and just actions from the High Court over the past nine months have reaffirmed our faith in the Indian legal system in securing the enforcement of patent rights and upholding of patient interests. This also underlines the strength of Boehringer Ingelheim’s patents."

In the last nine months, Boehringer Ingelheim has received the following injunctions against generic pharmaceutical companies for patent infringement of its innovator drugs Jardiance (Empagliflozin) and Trajenta (Linagliptin):

· Ad-interim injunction granted against Dr Reddy’s Laboratories for Empagliflozin which was eventually made absolute

· Ad-interim injunction granted against MSN Laboratories for Empagliflozin which was eventually made absolute

· Ad-interim injunction granted against MacLeods for Linagliptin which eventually was made absolute

· Ad-interim injunction granted against Eris Lifesciences for Linagliptin

· Ad-interim injunction granted against MSN Laboratories for Linagliptin

· Ad-interim injunction granted against Emcure Pharmaceuticals for Linagliptin

· Ad-interim injunction granted against Optimus Pharma for Linagliptin